Table 2 Incidence of various AEs comparing combined atezolizumab + chemotherapy and chemotherapy alone
Adverse Effects (AEs) | No. of studies | RR (95% CI) | p-value | I2 (%) | Statistical method |
|---|---|---|---|---|---|
Any AEs | 5 | 1.03 (0.97, 1.09) | 0.32 | 91 | Random effect |
Serious AEs | 4 | 1.38 (1.13, 1.68) | 0.002 | 0 | Fixed effect |
High grade AEs | 5 | 1.18 (1.07, 1.31) | 0.002 | 45 | Fixed effect |
Haematological AEs | 5 | 1.10 (0.98, 1.23) | 0.10 | 50 | Random effect |
Gastrointestinal AEs | 5 | 1.06 (0.89, 1.27) | 0.49 | 72 | Random effect |
Dermatological AEs | 5 | 1.16 (1.02, 1.31) | 0.02 | 6 | Fixed effect |
Pulmonary AEs | 4 | 1.36 (1.09, 1.71) | 0.007 | 44 | Fixed effect |
Liver AEs | 5 | 1.13 (0.94, 1.35) | 0.18 | 30 | Fixed effect |
Endocrine AEs | 4 | 3.77 (2.78, 5.11) | <0.00001 | 0 | Fixed effect |
Neurological AEs | 5 | 1.13 (1.00, 1.26) | 0.04 | 0 | Fixed effect |